Protara Therapeutics

Protara Therapeutics has appointed William Conkling as Chief Commercial Officer, bringing over two decades of experience in developing and commercializing cancer and rare disease therapeutics.

Novo Nordisk undergoes significant executive restructuring following the departure of EVP Camilla Sylvest, with rare disease leader Ludovic Helfgott taking over expanded commercial strategy responsibilities.

Protara Therapeutics' TARA-002 demonstrates strong efficacy in Phase 2 ADVANCED-2 trial for non-muscle invasive bladder cancer, achieving 72% six-month complete response rate across all BCG exposure levels.

Protara Therapeutics anticipates mid-2025 data from the ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer (NMIBC) patients, building on positive six-month results.

• Protara Therapeutics' TARA-002 demonstrated a 72% complete response rate in non-muscle invasive bladder cancer patients, regardless of prior BCG exposure. • In BCG-unresponsive patients, TARA-002 achieved a 100% complete response rate at six months, highlighting its potential in a registrational cohort. • CG Oncology's cretostimogene grenadenorepvec showed a 74.5% complete response rate in BCG-unresponsive patients, with a median duration of response exceeding 27 months. • Both TARA-002 and cretostimogene grenadenorepvec exhibited favorable tolerability profiles, with minimal treatment-related adverse events.

Protara Therapeutics' TARA-002 demonstrated a 72% six-month complete response rate in NMIBC patients across various BCG exposure statuses.

Protara Therapeutics is presenting interim Phase 2 data for TARA-002 in non-muscle invasive bladder cancer (NMIBC) at the SUO annual meeting.

Protara Therapeutics' TARA-002 shows promise in NMIBC treatment, with ADVANCED-2 trial results expected in Q4 2024, and positive interim data in Lymphatic Malformations.

Protara Therapeutics' IV Choline Chloride receives FDA Fast Track designation for treating choline deficiency in parenteral support patients.